COVID-19 Information

Medical Assistance & First Contact

A student who is showing symptoms, would like to schedule a test or a doctor's visit, or has been confirmed as infected with SARS-CoV-2 virus should immediately get in touch by e-mail via our priority first contact address This email address is being protected from spambots. You need JavaScript enabled to view it.. Please make sure to include your contact phone number.

In additon to that dormitory residents can use the following hotline: +48 507 434 364.

In case of severe and sudden medical emergency contact the medical emergency service directly at 999 or 112.

General Recommendations

 

You are encouraged to get familiar with the instructions of CDC (Centers for Disease Control and Prevention) on the use of cloth face coverings in order to prevent the spread of CONVID-19.

Reliable sources of information:

https://www.who.int/health-topics/coronavirus#tab=tab_1

https://www.cdc.gov/coronavirus/2019-ncov/index.html

Student Vaccination Program

1. Which vaccine will be used to vaccinate PUMS students and staff?

At present, Pfizer and BionTech vaccine is approved for distribution in the EU. In January, the European Medicines Agency shall decide on another manufacturer. The Government will distribute the vaccine and our hospitals receive the vaccine at least in the first periods of vaccination. Most certainly, clinical hospitals will receive Pfizer and BionTech vaccines.

2. Which body cells will be affected by the vaccine?

The vaccine integrates with the cells present at the injection site, there is no specificity, so they integrate with different cells. Such cells "infected" with mRNA of the vaccine-specific for spike protein then present the spike protein-specific peptides on their tissue compliance antigens, mainly of I class, and the full spike protein is at the same time secreted by the cells producing the protein to the microenvironment surrounding the injection site.  There, the protein is absorbed by macrophages and dendritic cells which present fragments of spike protein peptides on human leukocyte antigens HLA of I and II class, then moving towards the lymphatic glands where they stimulate proliferation of B cells and T cells specific for this type of protein, mainly CD4, Th1 and CD8.

3. Why mRNA from the vaccine cannot penetrate our nucleus? How does it work?

The vaccine contains mRNA which after being administered to a human body replicates only in the cytoplasm and does not get into the nucleus. Knowing the basics of medical biology, we know that it cannot interfere with human DNA (located in the nucleus). We can tell with full responsibility that the vaccine cannot modify or damage the genome.

4. Has the vaccine been sufficiently well tested?

The vaccine has undergone all restrictive phases of clinical trials. The time and population were comparable as in the previous trials of other vaccines or medicines. However, the data - trial results were developed quicker. Many teams have worked on them, analyzing them in detail after respective phases of clinical trials. The solution applied here was the so-called rolling review. Requirements for obtaining permission to trade with all medicinal products, including vaccines, are very stringent. They are specified in the European Commission's guidelines, International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The vaccine is approved in the so-called centralized procedure in which the application is examined by the Committee for Medicinal Products for Human Use.

5. Which institutions have tested the vaccine and where the information about the tests can be read?

Marketing a vaccine requires precisely planned clinical trials. They are organized by the sponsor of the trial, in this case, the manufacturer. Clinical trials are subject to restrictive legal regulations, inspections, and audits. They are subject to the credibility and reliability of clinical data control. In case of a standard registration mechanism for the EU, trial data is verified by the European Medicines Agency (EMA). EMA recommendations are taken into account by the European Commission in the approval procedure.

Useful information about the clinical trials process, registration, and results of tests on the vaccine is described on the websites:

• European Medicines Agency - ema.europa.eu/en
• Food and Drug Administration (USA) - https://www.fda.gov/
• NHS - https://www.nhs.uk/conditions/coronavirus-covid-19/

6. Is the vaccine safe for use if it was released so quickly, without completing the last phase of clinical trials?

The vaccine has undergone all phases of clinical trials - from I to III. Phase III, carried out under clinical practice conditions was the last phase required by law, before medicine or vaccine is approved for use. All procedures associated with clinical trials and the registration process have been completed. The enormous financial funds and engagement of numerous researcher teams from all over the world and the evaluation of research during each phase of the clinical trials caused the registration to take less time than usual. But the clinical trials were carried out just as they had been carried out so far.

The manufacturers started preparation for the vaccine production already during the review of documentation from clinical trials. This allowed the production lines to be prepared to manufacture the vaccines as soon as they were formally approved for use. Under normal conditions - without the pandemic - preparations for production commence only after all formal approvals are obtained. This also contributed to earlier receiving the vaccine as a ready-made product for administration in patients.

The European Medicines Agency's principal rule in evaluating the COVID-19 vaccine is: the advantages of the vaccines must considerably outweigh the potential risk for the patients. And this requirement has been met in case of COVID-19 vaccine.

7. How is it possible that the Covid vaccine was developed quickly, and no HIV vaccine had been developed for 40 years?

HIV is a relatively small virus which codes only a small number of small proteins and therefore very few naive cells for its recognition are available. Vaccines were produced, but due to, among others, the reason as mentioned above, their effectiveness was low. The larger number, and the bigger proteins are produced by a virus, the easier is their recognition by the immune system. Moreover, HIV attacks the immune system, T cells auxiliary to CD4 are needed to produce antibodies.

8. Will the vaccine be effective in case of the new mutation of the virus that appeared, e.g. in the United Kingdom? Does S protein which is aimed for by Pfizer vaccine not change by mutation?

It should be effective. The vaccine causes the production of polyclonal antibodies against different fragments of the virus proteins. One antibody conformatively recognizes protein sequence of over a dozen of amino acids. A fragment of corona protein responsible for connecting with the receptor of the target cell has circa 270 amino acids, i.e. there are plenty of spaces available for the amino acids, and they can overlap. If the protein is large, there are many different sites for fixation. Some antibodies see the "eye", others see the "nose" or "the big toe". However, the mutation can cause some singular epitopic specificities may "drop out", however not all, if the protein is big. It must be noted that the available number of fixation sites for antibodies in protein mutations may decrease. Theoretically, it is possible that the mutating virus modifies a protein to such an extent that the vaccine has little or no effect. However, the mutations affect its ability to fix to the cell. The chance that the virus mutates so much that there will be no fixation sites for amino acids, and at the same will be contagious, is very small for large proteins. Then, the vaccine would need to be modified. Vaccine effectiveness decreases as the number of proteins and their size decrease, and the propensity to mutate is higher, as happens with influenza.

9. How the vaccine will immunize us, if after the infection with a complete virus and recovering from the disease, we become immune for about six months only? Will this mean that we will be vaccinated every six months?

To be precise, we do not know how long the immunization effect lasts after recovering from the disease; I believe it is much longer than six months. After six months, even if it drops to a low level, there is still memory of T cells, which can last much longer, perhaps for several years. So, even if the antibodies level is decreased, the memory of their production remains as a "documentation in a factory" for much longer. Reinfection triggers the antibodies synthesis, not after two weeks, but takes much less time, it requires 2-5 days. It all depends on the strength of the T-cell response triggered, which is conditional upon the number of naive cells able to recognize immediately"". However, this ability may be limited by the virus itself, depending on the strength of the immunosuppressive effect. We know that SARS Cov2 may act like this, but we do not know to what extent. The vaccine is also repeated, the booster dose is administered after 3-4 weeks, and this considerably increases the count of memory cells, and new naive cells are produced in the marrow, and the cycle is repeated. There is data, that in medical staff, the antibodies last longer, which is logical, as the contact with the virus which triggers the immunological memory and increases antibodies production is repeated.

10. After getting Covid-19, how long do antibodies stay in the body?

In some people, they stay longer, in other shorter. It all depends on the initial level of antibodies and the memory ability of T cells. Usually, IgG antibodies drop to half the initial level in COVID-19 convalescents after approximately 3-6 months. It depends on the resultant length of contact with virus antigen, which after the end of infection may survive much longer, e.g. in the alimentary tract. The physiological process of antibodies level decrease is also of significance. However, one must remember that T-memory of virus proteins, and the potential new contact will "boost up" the level of antibodies and no symptoms of such contact will actually be felt. In consequence, the antibodies may stay in the body for much longer, and even if barely detectable, they may serve their protective role.

11. Why, before administering the vaccine to a person who recovered from COVID-19, no antibodies level is determined in order to check whether their number is sufficient to refrain from vaccination within the given time period?

Certainly, we can do that, but at the moment we do not know which level of antibodies is the protective level that would allow refraining from vaccination. Besides, in the case of reinfection, the body will treat it as another dose of the vaccine which will "boost up" the antibodies level, and prolong the memory.

12. What about people with chronic diseases?

Eligibility check is always performed by a doctor on the basis of medical history and physical examination.

The vaccine may increase the inclination to auto immunization, which is associated with relatively high secretion of m Interferon-alpha but this is a relative contraindication. At present, the explicit contraindications include the rare neurological Guillain-Barré syndrome, and previous incidents of anaphylactic shock after injections - there were reported two cases in the UK after the vaccination was started, but they concerned very sensitive persons who needed to carry syringes with adrenaline at all times.

13. Can the vaccine be taken by persons with an acute allergic reaction to chicken egg protein? The question results from the fact that all websites list the contraindication "strong allergic reaction to medicines, vaccines or food in the past", and which food allergies should be meant here?

These are relative contraindications, always subject to a decision made by the doctor. At present, the explicit contraindications include the rare neurological Guillain-Barré syndrome, and previous incidents of anaphylactic shock after injections - there were reported two cases in the UK after the vaccination was started, but they concerned very sensitive persons who needed to carry syringes with adrenaline at all times.

14. Can a person with a previous anaphylactic shock episode sign up for vaccination?

It is a significant contraindication.

15. Will COVID-19 vaccine be equally effective, although I have not been vaccinated against influenza?

The effectiveness is estimated at 90-95%, which is a very high number in the case of vaccines. Influenza vaccination has no significant connection with that.

16. How about the risk of the occurrence of leukemias as a distant undesired effect referred to by hematologists? Is there any connection between the vaccination and hematologic malignancies? Are potential mutations, e.g. neoplastic, caused by the vaccine possible after several years?

There are no such presumptions.

17. What is the risk of late complications after vaccination as there is no research after 3, 5 years, e.g. the risk of developing autoimmune diseases and other complications? Are they possible? What type of complications? Is it possible that cells become coated?

Vaccination can affect increased auto immunization through the stimulation of interferon-alpha production; it has been mentioned, but the infection itself boosts the effect much stronger which, in case of COVID-19 can be seen with regard to the nervous system and late complications.

18. In what time span (approximately) can PUMS students be expected to get vaccinated in the phase "0"?

It is most likely that vaccinations will take place in January and February, as regards the phase "0", which will include PUMS staff and students. However, it all depends on the distribution of vaccines and supplies to Poland.

19. Can the type of vaccine be chosen by the person to be vaccinated?

As of now, there is no possibility to choose the type of vaccination - it is not available in pharmaceutical distribution. Our clinical hospitals receive the vaccine distributed by the Government.

20. Will it be possible to be vaccinated with vaccines manufactured by other companies? AstraZeneca, Moderna?

It seems, from the analysis of assumptions of the vaccination program, that as of now there is no possibility to choose the type of vaccination by persons who want to be vaccinated. However, everybody will be informed about the type of vaccine to be used, and the serial number of the vaccine. Such data will be available in the patient's electronic account. In January, the European Medicines Agency is to consider the approval of Moderna vaccine, and according to official information from the Government, Poland is among the countries which have ordered Moderna vaccines.

21. Can we resign from the vaccination after we have signed up for it?

Vaccination is voluntary.

Please remember that the decision of the Rector about the arrangement of vaccinations for PUMS students and staff, is the expression of his care for the health of all of us, and to resume the routine activities of the University. As an academic society, we have the opportunity to be vaccinated.

It is allowed to resign from the declaration of vaccination. Should anyone of you make such a decision, this should take place before booking a specific date (for persons who send GDPR declaration electronic calendars will be made available). The vaccine distribution system and storage conditions impose a specific rigor of setting the dates of vaccinations. Unfrozen vaccines cannot be frozen again, they also have a specific administration deadline. Therefore, you are requested to make prudent decisions, especially during the phase of setting the dates of vaccinations.

22. Will there be consequences for those who are not vaccinated? (For example exclusion from taking part in practical classes)? Will the students, who choose not to get vaccinated in the first phase of vaccinations, face any consequences on the part of the University?

As we have already emphasized, the vaccination is voluntary. Therefore, one cannot speak about the consequences on the part of PUMS with regard to the students who do not want to get vaccinated. However, it may happen that there will be introduced national recommendations that vaccinated persons shall be excluded from the obligation to quarantine after contact with a COVID+ person.  Then, the vaccinated persons will be allowed to continue contact clinical classes, other persons will be required to stay in quarantine.

23. What happens if someone stays in quarantine or is ill at the time of the scheduled vaccination? Will there be additional dates set?

The vaccinations will be spread over a longer time, and for our community, it will presumably take two months. So, we will be able to move the date of vaccination. Of course, it will be important that you inform us about the inability to appear for vaccination on the date set as soon as the vaccines are delivered.

24. If we do not sign up for the vaccination arranged by PUMS but later on decide that we wish to be vaccinated, will it be possible to do it within a similar period? Or will it be necessary to wait for the later phase of vaccination?

At present, we are able to arrange vaccinations for you in the so-called phase "0", which is the phase dedicated to healthcare professionals' sector. Regarding their age, students will be qualified for vaccination on later dates. Therefore, we cannot guarantee to the persons who do not declare the will to get vaccinated now, that they can be vaccinated on other tight deadlines. We really encourage you to get vaccinated - it is safe!

25. Can I resign from vaccination without consequences? Until when can the application be withdrawn?

Application withdrawal is possible by the time of booking a specific vaccination date. After vaccination date has been set, withdrawal can only be possible due to important reasons. It may happen that due to health issues discovered during the examination by a doctor before the vaccination, the person will be disqualified. No consequences are foreseen for the resignation from the vaccination. However, due to reasons described above (distribution system, storage conditions and the effectiveness of the vaccination process) you are kindly requested not to overuse the potential possibility to withdraw. We must demonstrate our responsibility - millions of people are waiting for the vaccine, and not a single dose should be "wasted" due to our reckless decisions.

26. Would there be any other signing up date than 23.12.20?

We are not planning any additional dates - we are required to provide data of the persons declaring the will to be vaccinated until 28 December.

27. Will there be a medical examination qualifying for vaccination?

Yes, before administering the vaccine, a qualifying medical examination will be carried out by a doctor.

28. If a doctor decides that I am ineligible for vaccination, will I be required to pay for the vaccine?

Disqualification by the doctor before vaccination shall not burden the patient with the costs of vaccination.

29. Is there a guarantee that there will be no deficit in vaccines for the boost dose?

Such a guarantee is given by the governmental vaccination program and appropriate vaccine distribution system.

30. Will the stationary classes be restored after vaccination of students? If so, when can we expect them to be restored?

Such a decision will depend on the vaccination coverage among PUMS society, and legal regulations of the Minister of Health concerning education at medical universities. We would really wish that practical classes are carried out in a stationary form only. Apart from legal implications, the hypothetical restoration of the classes would be possible with an appropriate vaccination coverage in our population, i.e. at least 70-75%, which would significantly affect the reduction of infection risk at stationary classes.

31. Will there be ensured appropriate storage of the vaccine in such low temperatures everywhere? Are we really able to do that?

Vaccination stations will be arranged in our clinical hospitals, and in the phase "0" vaccinations for PUMS staff and students will be executed by PUMS Clinical Hospital Przemienienia Pańskiego. It is one of the leading hospitals in Poland, with CMJ accreditation, with highest safety standards - we can therefore guarantee proper vaccine storage conditions.

32. How does the vaccine work?

The vaccine contains mRNA with information about the structure of SARS-CoV-2 virus protein spike. The spike is the fusion fragment of the virus, used by it to fuse with human cells. Vaccine's mRNA is transported to some of the human cells in which the synthesis of spike protein takes place on this matrix, and which immunizes the human body. Antibodies (also the specific cellular immunity) are produced which, in case of virus penetration to a human body, trigger the immune reaction blocking the virus fusion with host cells. Thus triggered immune reaction defends the human organism against the development of the infection. It should be noted that the mRNA vaccine delivers a matrix (guide), and the human body uses it to produce an antigen on its own, against which the defending reaction is triggered. In this technology, no virus is delivered to the human body.

33. Why the vaccine is developed on the basis of a new technology that has never been used before, instead of the traditional method?

The new technology has many advantages in comparison to the traditional methods:

1. after identifying a significant fragment of the virus, there is identified the gene/genes that control its synthesis, and then the significant information is transcribed into mRNA;
2. mRNA is produced in vitro, no viral culture, expensive substrates, or time to grow the virus are required;
3. in this technology no virus is introduced to the human body, which is much safer;
4. after confirmed effectiveness of the vaccine, its production is quick and very efficient, which is of significance in production for the pandemic demand (large quantities of the vaccine produced in a relatively short time)

34. How is the vaccine's effectiveness tested? Is the control and studied group infected with the virus? As the infection percentage in the control group is low, please explain the research on the effectiveness of the vaccine.

About 44,000 people were declared eligible for the clinical trial, half of them had the vaccine, and the other half had a placebo administered. Random allocation and double-blind trial method. Infections were observed in both arms of the trial. In the placebo arm, 162 persons got infected, and in the vaccinated persons arm, nine persons were infected. Therefore the effectiveness amounts to approximately 95%.

35. How long does the vaccine provide protection against getting ill? Should it be administered repeatedly, e.g. once a year, as in case of the influenza vaccine?

At this stage, it is hard to predict how long the effective protection will last. To obtain a high concentration of antibodies, the double-dose scheme is applied, and the experience from other vaccines shows that a high concentration of antibodies is getting reduced slower. It is assumed that the protection shall be effective for at least two years, and this would allow putting an end to the pandemic.

36. Did the vaccine tests actually prove its effectiveness in preventing the virus, or just the disease symptoms? In the second instance, the vaccinated persons would pose an equally high risk. I am referring here to the claims of American medics and "The Atlantic" magazine (Ed Yong).

In the research, the endpoint was COVID-19 disease, i.e. asymptomatic disease. Does it prevent symptoms-free infections? We do not know yet. Population safety must be based on collective immunity, which means that most of the population should be vaccinated. 

37. As medical students, should we get vaccinated despite our young age? (The inquirer is most likely afraid of the long-term effects of the vaccination, therefore is referring to the age).

Medical students participate in classes in direct contact with patients, so, on the one hand, they are exposed to infection, and on the other hand, in case of mild, symptoms-free infection they may pose a deadly threat to many patients (elderly, immunosuppressed, or transplantation patients etc.) It is hard to imagine the possibility to have people working in medical professions who voluntarily decided that they did not want to be vaccinated.

38. Is it worth getting vaccinated if one has already recovered from coronavirus?

We do not know how long the immunity will last. There have been reported cases of re-infection. Therefore, the convalescents all over the world are recommended to get vaccinated.

39. Should the person who did undergo Covid with heavy/mild symptoms / or symptoms-free get vaccinated?

We do not know how long the immunity will last. There have been reported cases of re-infection. Therefore, the convalescents all over the world are recommended to get vaccinated.

We do not know whether the intensity of the symptoms is the only indicator of the antibodies concentration in a specific person. Probably it is not. The significant role is played by the condition of the immune system.  

40. If it is possible to get vaccinated after recovering from covid-19 - how much time one should wait?

It is believed that one should wait at least 30 days from the end of treatment/isolation.

41. After what amount of time after vaccination shall we gain sufficient immunity to be protected against SARS-CoV-2 infection?

Seven days after the boost dose.

42. Are there already any clear contraindications to vaccination? Who should not get vaccinated?

At present, the contraindications include pregnancy, breastfeeding, previous anaphylactic shock in response to vaccine ingredients (mainly polyethene glycol), or to the primary dose of the vaccine.

43. Pregnancy and breastfeeding - are these the contraindications?

Yes, they are.

44. I am allergic to salicylates, I have had a previous record of anaphylactic shock, what is the risk if I get vaccinated?

The qualifying doctor will verify whether the anaphylactic shock was consistent with the diagnosis criteria and whether the allergic reaction was actually caused by salicylates. Depending on that, the doctor will decide whether the person can be vaccinated or not.

45. What are the potential side effects of the vaccine?

In 2-3 days after vaccination, patients may develop fever, shivers, pain in the injection site, headaches, fatigue, sleepiness. The symptoms do not last long. There have been described singular cases of anaphylactic shock - with the incidence of 1-2 people out of 100,000 vaccinated.  

46. How, within a year, the side effects that may occur within years, have been tested?

We do not know the side effects that may occur several years after (any) vaccination.

47. How probable it is that an allergic reaction will occur several years after the vaccination?

Allergic reactions to vaccination occur within several days, and dangerous reactions (e.g. anaphylactic shock) occur within minutes after vaccination.

48. What kind of vaccination will it be - in the form of an ampoule-syringe or a vial?

The vaccine is supplied in a vial, and its quantity is sufficient to vaccinate 5 persons (0.3 ml per person).

49. Can the potential errors in storing the vaccine cause that it becomes dangerous, or rather it will lose its properties?

First of all, the vaccine could become ineffective. During transportation, the container with the vaccine holds special recorders which can be read after unpacking to check the temperature range under the transport.

50. What can the consequences of prior improper transportation and storage of vaccine be for the vaccinated?

Should there be discovered a breach of transport conditions, the vaccine would not be used for vaccination.

Changes in Organization of Teaching

Traveling to Poznan

A. Students arriving at PUMS from abroad to start classes are required to:

1. Pre-travel test: Take a PCR SARS-CoV-2 test within 72h prior to departure to Poznan and submit the results of this test to the Dean’s Office by e-mail upon arrival (to your respective class coordinator).
   Cannot provide the above pre-travel test result upon arrival? You will be required to take the test upon arrival in the PUMS CoViD Lab at your own expense, and stay in self-isolation until receiving negative test result.
2. Post-travel test: Take a second PCR test at the University CoViD Lab 7 days after arrival (free of charge).

Only students whose results are negative in both tests will be allowed to participate in in-person classes.

 

B. Students arriving at PUMS dormitories (both current residents and those moving in) are also required to undergo pre- and post-travel tests and are additionally required to present both test results to the Dormitory Administration via e-mail (This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it. – the latter address serves for both Medyk and Aspirynka). Please e-mail your pre-travel test results before departure so that we have time to clear you as an approved resident.

Cannot provide the pre-travel test result? You will be assigned University-run quarantine accommodation suitable for self-isolation until receiving negative test results – please get in touch with the Manager of Student Housing, Mr. Miroslaw Jackowiak, as soon as you know your travel plans to arrange that in advance at This email address is being protected from spambots. You need JavaScript enabled to view it. or +48 507 434 364.

 

C. All tests at PUMS CoViD Lab require students to self-register on-line. A designated English-language form for this purpose will be available shortly.

 

Traveling from non-EU countries

In its recent regulations, the Council of the European Union, has announced that the external borders of the European Union will be re-opened to non-essential travelers from specific outside countries. The allowed list currently does not include the USA or many other home countries of our students, but it will be updated every two weeks.

The important fact is that students are exempted from these travel restrictions as traveling for the purpose of studying is considered essential travel. It is very important that you secure your student visa to Poland ahead of time (or Polish citizenship, temporary stay permit), because the document might be required (along with your university proof of enrollment) to be allowed into Poland. Detailed information can be obtained from your local Polish consulate.

This is the legal basis for the travel ban, along with all the exceptions: https://data.consilium.europa.eu/doc/document/ST-9208-2020-INIT/en/pdf, and here is the clarification by the New York Times: https://www.nytimes.com/article/eu-travel-ban-explained-usa.html.

Please note that students are currently exempted from quarantine upon entering the European Union.

Travel from UK may be restricted because of discovery of a new strain of the SARS-CoV-2.

Restrictions Imposed by the Polish Government

Immigration Documents

Please review information on this website for instructions on how to extend your legal stay in Poland or address your immigration issues with local government offices during the state of epidemic.

All visas, residence cards and work permits expiring during the current state of epidemic in Poland are automatically extended until 30 days after the official announcement of the end of the epidemic. This also applies to deadlines to submit applications and orders to leave the country: https://udsc.gov.pl/en/coronavirus-outbreak-special-solutions-for-foreigners/.

The Anti-Crisis Shield

Where to Look for Help

Students who are in quarantine or isolation and need assistance with shopping and other necessities can contact EPSU and link up with volunteers who will be happy to help: This email address is being protected from spambots. You need JavaScript enabled to view it.. Alternatively, you can contact another similar initiative by RUSS and IFMSA as indicated in the poster below:

Voluntary Opportunities

It is now possible for English-speaking students to apply for volunteering position in one of the hospitals in Poznan. If you are interested and willing to help, the application form is available through your VISUS account. If you have any questions regarding volunteering, you can call 61 854 72 21 (7:30 a.m.-3:00 p.m.)

Please refer to EPSU Charity & Volunteering Club for a list of volunteering opportunities at https://www.facebook.com/groups/EPSUCharityVolunteering/.

Rector's Special Regulations

Rector's Resolution No. 147/20 and related guidelines

Rector's Resolution No. 144/20

Rector's Resolution No. 130/20

Rector's Resolution No. 124/20

Rector's Resolution No. 104/20

Rector's Resolution No. 43/20

Rector's Resolution No. 35/20

Rector's Resolution No. 33/20

Rector's Resolution No. 31/20

Rector's Resolution No. 28/20

Rector's Resolution No. 23/20

Rector's announcement concerning e-learning